Filing Details

Accession Number:
0001437749-21-003518
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-19 20:02:15
Reporting Period:
2021-02-08
Accepted Time:
2021-02-19 20:02:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
834365 Biolife Solutions Inc BLFS Electromedical & Electrotherapeutic Apparatus (3845) 943076866
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1683151 A. Karen Foster C/O Biolife Solutions, Inc.
3303 Monte Villa Parkway, Suite 310
Bothell WA 98021
Chief Quality Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-02-08 4,157 $0.00 54,899 No 4 A Direct
Common Stock Acquisiton 2021-02-08 23,336 $0.00 78,235 No 4 M Direct
Common Stock Disposition 2021-02-17 3,281 $41.55 74,954 No 4 S Direct
Common Stock Disposition 2021-02-18 3,353 $40.67 71,601 No 4 S Direct
Common Stock Disposition 2021-02-19 3,344 $40.76 68,257 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Award Acquisiton 2021-02-08 4,157 $0.00 4,157 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
4,157 No 4 A Direct
Footnotes
  1. The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2021 compensation.
  2. The reporting person was granted restricted stock pursuant to the Plan on February 25, 2019. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
  3. The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
  4. The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.